BAGANBAZAR GRAPHEXPLORE · ANALYZE · GROW
Theme
LiveDesk
World/Source-attributed reporting

Pharma major Novartis falls nearly 10%, heading for worst day on record after three drug trial setbacks

Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.

Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
ORIGINAL SOURCE

Consumer News and Business Channel

This report is indexed by BAGANBAZAR GRAPH with its original publisher named and linked for readers.

Read at original outlet ↗